Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.43 |
| ▸ | USP2 | O75604 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | DHODH | Q02127 | 7/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30738512 | 1.00 | LMNA (0.43) | LMNACYP1A2CYP3A4CLK4USP2 | |
| SCHEMBL22179952 | 0.85 | NAMPT (0.41) | LMNACYP1A2CYP3A4CLK4USP2 | |
| SCHEMBL23965728 | 0.81 | MAP4K4 (0.36) | LMNACYP1A2CYP3A4CLK4USP2 | |
| SCHEMBL30738319 | 0.77 | ADORA2A (0.59) | LMNACYP1A2CYP3A4CLK4USP2 | |
| SCHEMBL20392686 | 0.77 | ADORA2A (0.59) | LMNACYP1A2CYP3A4CLK4USP2 | |
| SCHEMBL21621174 | 0.76 | ADORA1 (0.46) | CYP1A2CLK4ABL1MAP4K4POLB | |
| SCHEMBL22179956 | 0.75 | NPC1 (0.42) | LMNACYP1A2CYP3A4CLK4USP2 | |
| SCHEMBL30738378 | 0.75 | NPC1 (0.42) | LMNACYP1A2CYP3A4CLK4USP2 | |
| SCHEMBL21621285 | 0.74 | MAP4K4 (0.46) | LMNACYP1A2CYP3A4CLK4USP2 | |
| SCHEMBL29947049 | 0.74 | MAP4K4 (0.46) | LMNACYP1A2CYP3A4CLK4USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210395226-A1 | SUBSTITUTED ARYL COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2021-12-23 | — | — | US | disclosed |
| WO-2020135210-A1 | SUBSTITUTED ARYL COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2020-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395226-A1 | SUBSTITUTED ARYL COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | ADORA2A, ADORA1, ADORA3 | LMNA 1702/4885CYP1A2 257/4885CYP3A4 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.